Возможности современных биомаркеров для оценки риска развития желудочковых тахиаритмий и внезапной сердечной смерти у больных хронической сердечной недостаточностью
Аннотация
Современные биомаркеры позволяют диагностировать широкий спектр патологических процессов, протекающих в организме, оценивать эффективность терапевтических воздействий и прогноз кардиологических больных. Настоящий обзор посвящен возможностям использования N-терминального фрагмента предшественника мозгового натрийуретического пептида (NT-proBNP), растворимого супрессора туморогенности 2-го типа (sST2), галектина-3 и других биомаркеров у больных хронической сердечной недостаточностью для оценки риска развития жизнеугрожающих желудочковых тахиаритмий и возникновения внезапной сердечной смерти.
Об авторах
А. Ж. Гаспарян
ФГБУ "НМИЦ Кардиологии" МЗ РФ
Россия
аспирант отдела клинической электрофизиологии и рентгенохирургических методов лечения нарушений ритма сердца ИКК им.А.Л.Мясникова ФГБУ «НМИЦ Кардиологии» МЗ РФ. 3-я Черепковская 15А, г. Москва 121552.
Россия
аспирант отдела клинической электрофизиологии и рентгенохирургических методов лечения нарушений ритма сердца ИКК им.А.Л.Мясникова ФГБУ «НМИЦ Кардиологии» МЗ РФ. 3-я Черепковская 15А, г. Москва 121552.
Н. Б. Шлевков
ФГБУ "НМИЦ Кардиологии" МЗ РФ
Россия
Россия
старший научный сотрудник лаборатории отдела клинической электрофизиологии и рентгенохирургических методов лечения нарушений ритма сердца ИКК им.А.Л.Мясникова ФГБУ «НМИЦ Кардиологии» МЗ РФ, к.м.н. 3-я Черепковская 15А, г. Москва 121552.
А. А. Скворцов
ФГБУ "НМИЦ Кардиологии" МЗ
Россия
ведущий научный сотрудник отдела заболеваний миокарда и сердечной недостаточности ИКК им.А.Л.Мясникова ФГБУ «НМИЦ Кардиологии» МЗ РФ, д.м.н. 3-я Черепковская 15А, г. Москва 121552
Россия
ведущий научный сотрудник отдела заболеваний миокарда и сердечной недостаточности ИКК им.А.Л.Мясникова ФГБУ «НМИЦ Кардиологии» МЗ РФ, д.м.н. 3-я Черепковская 15А, г. Москва 121552
Список литературы
1. Zipes DP. Epidemiology and mechanisms of sudden cardiac death. The Canadian Journal of Cardiology. 2005;21(Suppl A):37A-40A. PMID: 15953943
2. Shen L, Jhund PS, Petrie MC, Claggett BL, Barlera S, Cleland JGF et al. Declining risk of sudden death in heart failure. New England Journal of Medicine. 2017;377(1):41–51. DOI: 10.1056/NEJMoa1609758
3. Ezekowitz JA, Rowe BH, Dryden DM, Hooton N, Vandermeer B, Spooner C et al. Systematic Review: Implantable Cardioverter Defibrillators for Adults with Left Ventricular Systolic Dysfunction. Annals of Internal Medicine. 2007;147(4):251–62. DOI: 10.7326/0003-4819-147-4-200708210-00007
4. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). European Heart Journal. 2015;36(41):2793–867. DOI: 10.1093/eurheartj/ehv316
5. Køber L, Thune JJ, Nielsen JC, Haarbo J, Videbæk L, Korup E et al. Defibrillator implantation in patients with nonischemic systolic heart failure. New England Journal of Medicine. 2016;375(13):1221–30. DOI: 10.1056/NEJMoa1608029
6. Mareev V.Yu., Fomin I.V., Ageev F.T., Begrambekova Yu.L., Vasyuk Yu.A., Garganeeva A.A. et al. Russian Heart Failure Society, Russian Society of Cardiology. Russian Scientific Medical Society of Internal Medicine Guidelines for Heart failure: chronic (CHF) and acute decompensated (ADHF). Diagnosis, prevention and treatment. Kardiologiia. 2018;58(6S):8–164. [Russian: Мареев В. Ю., Фомин И. В., Агеев Ф. Т., Беграмбекова Ю. Л., Васюк Ю. А., Гарганеева А. А. и др. Клинические рекомендации ОССН – РКО – РНМОТ. Сердечная недостаточность: хроническая (ХСН) и острая декомпенсированная (ОДСН). Диагностика, профилактика и лечение. Кардиология. 2018;58(6S):8-164]. DOI: 10.18087/cardio.2475
7. Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure. 2019;21(10):1169–86. DOI: 10.1002/ejhf.1531
8. Cygankiewicz I, Zareba W, Vazquez R, Bayes-Genis A, Pascual D, Macaya C et al. Risk Stratification of Mortality in Patients with Heart Failure and Left Ventricular Ejection Fraction >35%. The American Journal of Cardiology. 2009;103(7):1003–10. DOI: 10.1016/j.amjcard.2008.11.061
9. Fomin I.V. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016;8:7–13. [Russian: Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский Кардиологический Журнал. 2016;8:7-13]. DOI: 10.15829/1560-4071-2016-8-7-13
10. Kelder JC, Cowie MR, McDonagh TA, Hardman SMC, Grobbee DE, Cost B et al. Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis. Heart. 2011;97(12):959–63. DOI: 10.1136/hrt.2010.220426
11. Nakagawa O, Ogawa Y, Itoh H, Suga S, Komatsu Y, Kishimoto I et al. Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an ‘emergency’ cardiac hormone against ventricular overload. Journal of Clinical Investigation. 1995;96(3):1280–7. DOI: 10.1172/JCI118162
12. Yasue H, Yoshimura M, Sumida H, Kikuta K, Kugiyama K, Jougasaki M et al. Localization and mechanism of secretion of B-type natriuretic peptide in comparison with those of A-type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 1994;90(1):195–203. DOI: 10.1161/01.CIR.90.1.195
13. Iwanaga Y, Nishi I, Furuichi S, Noguchi T, Sase K, Kihara Y et al. B-type natriuretic peptide strongly reflects diastolic wall stress in patients with chronic heart failure: comparison between systolic and diastolic heart failure. Journal of the American College of Cardiology. 2006;47(4):742–8. DOI: 10.1016/j.jacc.2005.11.030
14. Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM et al. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement from the American Heart Association. Circulation. 2017;135(22):e1054–91. DOI: 10.1161/CIR.0000000000000490
15. Levine YC, Rosenberg MA, Mittleman M, Samuel M, Methachittiphan N, Link M et al. B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias. Heart Rhythm. 2014;11(7):1109–16. DOI: 10.1016/j.hrthm.2014.04.024
16. Klein G, Lissel C, Fuchs A-C, Gardiwal A, Oswald H, deSousa M et al. Predictors of VT/VF-occurrence in ICD patients: results from the PROFIT-Study. EP Europace. 2006;8(8):618–24. DOI: 10.1093/europace/eul082
17. Cheng A, Zhang Y, Blasco-Colmenares E, Dalal D, Butcher B, Norgard S et al. Protein Biomarkers Identify Patients Unlikely to Benefit from Primary Prevention Implantable Cardioverter Defibrillators: Findings from the Prospective Observational Study of Implantable Cardioverter Defibrillators (PROSE-ICD). Circulation: Arrhythmia and Electrophysiology. 2014;7(6):1084–91. DOI: 10.1161/CIRCEP.113.001705
18. Scott PA, Barry J, Roberts PR, Morgan JM. Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis. European Journal of Heart Failure. 2009;11(10):958–66. DOI: 10.1093/eurjhf/hfp123
19. Muthu V, Kozman H, Liu K, Smulyan H, Villarreal D. Cardiac Troponins: Bench to Bedside Interpretation in Cardiac Disease. The American Journal of the Medical Sciences. 2014;347(4):331–7. DOI: 10.1097/MAJ.0b013e31829107ea
20. Kociol RD, Pang PS, Gheorghiade M, Fonarow GC, O’Connor CM, Felker GM. Troponin Elevation in Heart Failure prevalence, mechanisms, and clinical implications. Journal of the American College of Cardiology. 2010;56(14):1071–8. DOI: 10.1016/j.jacc.2010.06.016
21. Weinberg EO, Shimpo M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD et al. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. Circulation. 2002;106(23):2961–6. DOI: 10.1161/01.cir.0000038705.69871.d9
22. Medina A, Moss AJ, McNitt S, Zareba W, Wang PJ, Goldenberg I. Brain natriuretic peptide and the risk of ventricular tachyarrhythmias in mildly symptomatic heart failure patients enrolled in MADIT-CRT. Heart Rhythm. 2016;13(4):852–9. DOI: 10.1016/j.hrthm.2015.12.024
23. Usuku H, Nakayama M, Sumida H, Yamamuro M, Izumiya Y, Suzuki S et al. Pump failure death and sudden cardiac death in patients with cardiac dysfunction: A search for prognostic predictive factors – A long-term follow-up study. Journal of Cardiology. 2010;55(1):55–64. DOI: 10.1016/j.jjcc.2009.08.005
24. Biasucci LM, Bellocci F, Landolina M, Rordorf R, Vado A, Menardi E et al. Risk stratification of ischaemic patients with implantable cardioverter defibrillators by C-reactive protein and a multi-markers strategy: results of the CAMI-GUIDE study. European Heart Journal. 2012;33(11):1344–50. DOI: 10.1093/eurheartj/ehr487
25. Sanada S, Hakuno D, Higgins LJ, Schreiter ER, McKenzie ANJ, Lee RT. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. Journal of Clinical Investigation. 2007;117(6):1538–49. DOI: 10.1172/JCI30634
26. Kakkar R, Lee RT. The IL-33/ST2 pathway: therapeutic target and novel biomarker. Nature Reviews Drug Discovery. 2008;7(10):827–40. DOI: 10.1038/nrd2660
27. Rehman SU, Mueller T, Januzzi JL. Characteristics of the Novel Interleukin Family Biomarker ST2 in Patients with Acute Heart Failure. Journal of the American College of Cardiology. 2008;52(18):1458–65. DOI: 10.1016/j.jacc.2008.07.042
28. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH et al. 2013 ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2013;128(16):e240-327. DOI: 10.1161/CIR.0b013e31829e8776
29. Pascual-Figal DA, Ordoñez-Llanos J, Tornel PL, Vázquez R, Puig T, Valdés M et al. Soluble ST2 for Predicting Sudden Cardiac Death in Patients with Chronic Heart Failure and Left Ventricular Systolic Dysfunction. Journal of the American College of Cardiology. 2009;54(23):2174–9. DOI: 10.1016/j.jacc.2009.07.041
30. Skali H, Gerwien R, Meyer TE, Snider JV, Solomon SD, Stolen CM. Soluble ST2 and Risk of Arrhythmias, Heart Failure, or Death in Patients with Mildly Symptomatic Heart Failure: Results from MADIT-CRT. Journal of Cardiovascular Translational Research. 2016;9(5–6):421–8. DOI: 10.1007/s12265-016-9713-1
31. Ahmad T, Fiuzat M, Neely B, Neely ML, Pencina MJ, Kraus WE et al. Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients with Chronic Heart Failure. JACC: Heart Failure. 2014;2(3):260–8. DOI: 10.1016/j.jchf.2013.12.004
32. Lupón J, Cediel G, Moliner P, de Antonio M, Domingo M, Zamora E et al. A bio-clinical approach for prediction of sudden cardiac death in outpatients with heart failure: The ST2-SCD score. International Journal of Cardiology. 2019;293:148–52. DOI: 10.1016/j.ijcard.2019.05.046
33. Sharma UC, Pokharel S, van Brakel TJ, van Berlo JH, Cleutjens JPM, Schroen B et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation. 2004;110(19):3121–8. DOI: 10.1161/01.CIR.0000147181.65298.4D
34. Nguyen M-N, Su Y, Vizi D, Fang L, Ellims AH, Zhao W-B et al. Mechanisms responsible for increased circulating levels of galectin-3 in cardiomyopathy and heart failure. Scientific Reports. 2018;8(1):8213. DOI: 10.1038/s41598-018-26115-y
35. Liu Y-H, D’Ambrosio M, Liao T -d., Peng H, Rhaleb N-E, Sharma U et al. N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. AJP: Heart and Circulatory Physiology. 2008;296(2):H404–12. DOI: 10.1152/ajpheart.00747.2008
36. Yu L, Ruifrok WPT, Meissner M, Bos EM, van Goor H, Sanjabi B et al. Genetic and Pharmacological Inhibition of Galectin-3 Prevents Cardiac Remodeling by Interfering with Myocardial Fibrogenesis. Circulation: Heart Failure. 2013;6(1):107–17. DOI: 10.1161/CIRCHEARTFAILURE.112.971168
37. De Boer RA, Voors AA, Muntendam P, van Gilst WH, van Veldhuisen DJ. Galectin-3: a novel mediator of heart failure development and progression. European Journal of Heart Failure. 2009;11(9):811–7. DOI: 10.1093/eurjhf/hfp097
38. de Boer RA, Lok DJA, Jaarsma T, van der Meer P, Voors AA, Hillege HL et al. Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction. Annals of Medicine. 2011;43(1):60–8. DOI: 10.3109/07853890.2010.538080
39. Zhang Y, Zhang R, An T, Huang Y, Guo X, Yin S et al. The Utility of Galectin-3 for Predicting Cause-Specific Death in Hospitalized Patients with Heart Failure. Journal of Cardiac Failure. 2015;21(1):51–9. DOI: 10.1016/j.cardfail.2014.10.006
40. Francia P, Adduci C, Semprini L, Borro M, Ricotta A, Sensini I et al. Osteopontin and Galectin-3 Predict the Risk of Ventricular Tachycardia and Fibrillation in Heart Failure Patients with Implantable Defibrillators: OPN and Gal-3 Predict VT/VF in Heart Failure Patients. Journal of Cardiovascular Electrophysiology. 2014;25(6):609–16. DOI: 10.1111/jce.12364
41. Oz F, Onur I, Elitok A, Ademoglu E, Altun I, Bilge AK et al. Galectin-3 correlates with arrhythmogenic right ventricular cardiomyopathy and predicts the risk of ventricular arrhythmias in patients with implantable defibrillators. Acta Cardiologica. 2017;72(4):453–9. DOI: 10.1080/00015385.2017.1335371
42. Hartupee J, Mann DL. Positioning of Inflammatory Biomarkers in the Heart Failure Landscape. Journal of Cardiovascular Translational Research. 2013;6(4):485–92. DOI: 10.1007/s12265-013-9467-y
43. Liu H, Guo X, Yao K, Wang C, Chen G, Gao W et al. Pentraxin-3 Predicts Long-Term Cardiac Events in Patients with Chronic Heart Failure. BioMed Research International. 2015;2015:817615. DOI: 10.1155/2015/817615
44. Scott PA, Rosengarten JA, Curzen NP, Morgan JM. Late gadolinium enhancement cardiac magnetic resonance imaging for the prediction of ventricular tachyarrhythmic events: a meta-analysis. European Journal of Heart Failure. 2013;15(9):1019–27. DOI: 10.1093/eurjhf/hft053
45. Priori SG, Blomström-Lundqvist C, Mazzanti A, Blom N, Borggrefe M, Camm J et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Europace. 2015;17(11):1601–87. DOI: 10.1093/europace/euv319
46. Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA et al. Myocardial Iodine-123 Meta-Iodobenzylguanidine Imaging and Cardiac Events in Heart Failure. Results of the Prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) Study. Journal of the American College of Cardiology. 2010;55(20):2212–21. DOI: 10.1016/j.jacc.2010.01.014
47. Lishmanov Yu.B., Zavadovsky K.V., Efimova I.Yu., Krivonogov N.G., Vesnina Zh.V., Sazonova S.I. et al. Prospects of nuclear medicine for the diagnosis of cardiovascular diseases. Siberian Medical Journal (Tomsk). 2015;30(2):21–9. [Russian: Лишманов Ю. Б., Завадовский К. В., Ефимова И. Ю., Кривоногов Н. Г., Веснина Ж. В., Сазонова С. И. и др. Возможности ядерной медицины в диагностике сердечно-сосудистых заболеваний. Сибирский Медицинский Журнал (г. Томск). 2015;30(2):21-9]
48. Bauer A, Zürn CS, Schmidt G. Heart Rate Turbulence to Guide Treatment for Prevention of Sudden Death. Journal of Cardiovascular Pharmacology. 2010;55(6):531–8. DOI: 10.1097/FJC.0b013e3181d4c973
49. Huikuri HV, Exner DV, Kavanagh KM, Aggarwal SG, Mitchell LB, Messier MD et al. Attenuated recovery of heart rate turbulence early after myocardial infarction identifies patients at high risk for fatal or near-fatal arrhythmic events. Heart Rhythm. 2010;7(2):229–35. DOI: 10.1016/j.hrthm.2009.11.004
50. Gatzoulis KA, Tsiachris D, Arsenos P, Antoniou C-K, Dilaveris P, Sideris S et al. Arrhythmic risk stratification in post-myocardial infarction patients with preserved ejection fraction: the PRESERVE EF study. European Heart Journal. 2019;40(35):2940–9. DOI: 10.1093/eurheartj/ehz260
При поддержке: Конфликт интересов: не заявлен.
Для цитирования:
Гаспарян А.Ж., Шлевков Н.Б., Скворцов А.А. Возможности современных биомаркеров для оценки риска развития желудочковых тахиаритмий и внезапной сердечной смерти у больных хронической сердечной недостаточностью. Кардиология. 2020;60(4):101-108. https://doi.org/10.18087/cardio.2020.4.n487
For citation:
Gasparyan A.Zh., Shlevkov N.B., Skvortsov A.A. Possibilities of modern biomarkers for assessing the risk of developing ventricular tachyarrhythmias and sudden cardiac death in patients with chronic heart failure. Kardiologiia. 2020;60(4):101-108. (In Russ.) https://doi.org/10.18087/cardio.2020.4.n487
Просмотров: 505
Послать статью по эл. почте 
Оставить комментарий 